Detalhe da pesquisa
1.
Covariate adjusted meta-analytic predictive (CA-MAP) prior for historical borrowing using patient-level data.
J Biopharm Stat
; : 1-9, 2024 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38562017
2.
Bayesian Additive Regression Trees (BART) with covariate adjusted borrowing in subgroup analyses.
J Biopharm Stat
; 32(4): 613-626, 2022 07 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35737650
3.
Bayesian analysis of survival data with missing censoring indicators.
Biometrics
; 77(1): 305-315, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32282929
4.
Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.
Stat Med
; 40(14): 3385-3399, 2021 06 30.
Artigo
Inglês
| MEDLINE | ID: mdl-33851441
5.
Propensity-score-based meta-analytic predictive prior for incorporating real-world and historical data.
Stat Med
; 40(22): 4794-4808, 2021 09 30.
Artigo
Inglês
| MEDLINE | ID: mdl-34126656
6.
Bayesian Semi-parametric Design (BSD) for adaptive dose-finding with multiple strata.
J Biopharm Stat
; 30(5): 806-820, 2020 09 02.
Artigo
Inglês
| MEDLINE | ID: mdl-32129133
7.
Evolution of Phase II Oncology Trial Design: from Single Arm to Master Protocol.
Ther Innov Regul Sci
; 57(4): 823-838, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-36871111
8.
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer.
Expert Rev Anticancer Ther
; 23(1): 95-106, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-36537204
9.
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
Blood Adv
; 6(19): 5550-5555, 2022 10 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35470385
10.
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
JAMA Oncol
; 7(12): e214761, 2021 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34647988
11.
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial.
Cancer Discov
; 11(7): 1688-1699, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-33632775
12.
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
Blood Adv
; 5(23): 5098-5106, 2021 12 14.
Artigo
Inglês
| MEDLINE | ID: mdl-34507350
13.
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
Eur J Cancer
; 148: 411-421, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33794441
14.
Flexible Bayesian subgroup analysis in early and confirmatory trials.
Contemp Clin Trials
; 98: 106149, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32942055
15.
Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.
Eur J Cancer
; 133: 120-130, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32502876
16.
Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials.
Contemp Clin Trials
; 54: 48-59, 2017 03.
Artigo
Inglês
| MEDLINE | ID: mdl-28089763